Antiviral drugs for pandemic preparedness Viral pandemics are not a once-in-a-lifetime event but a constant threat looming over our heads. While the fight against SARS-CoV-2 is currently a top priority, we should not lose sight of what might … more ➔
Roche’s IL-6 receptor blocker fails in Phase IIIRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question. more ➔
Enthera Pharmaceuticals Srl raises €28m in Series A financing Italian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease. more ➔
Vital expertise in oncolytic virus productionOncolytic viruses, viral vectors for gene therapy and viral-vectored prophylactic vaccines, are new, innovative, and already successful approaches for the treatment of severe diseases. The production … more ➔
Polyphor AG bags CHF19.3 in equity financingSwiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing. more ➔
A plucked chicken named Horizon Europe According to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked … more ➔
Defining the bioprocess is early quality control As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function … more ➔
Quantro: Seed capital by Evotec and Boehringer Germany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec … more ➔
Sourcing reference productsA biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ … more ➔
Targeting coronavirusesViennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting … more ➔
